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found in the literature (min 22.90%, max 42.80%), treatment
with starting dose DA 500 mg Q3W resulted in a BI that were
35.64% and 27.64% lower than EPOalfa 10,000 UI TIW and
40,000 UI QW respectively and 35.59% and 17.11% lower than
EPObeta 10,000 UI TIW and 30,000 UI QW respectively. The
results of the base case did not change in any of the sensitivity
scenarios. CONCLUSION: The model shows that treatment of
CIA with starting dose DA 500 mg Q3W is the rapeutic strategy
with lower mean cost per patient for all the analyzed scenarios
in Spain.
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OBJECTIVE: Development of a decision analytic model to esti-
mate the budget impact on the Swedish health service of using a
more effective diagnostic tool in conjunction with white light
cystoscopy (WLC) in the management of superﬁcial bladder
cancer (SBC). Hexvix (hexaminolevulinate) ﬂuorescence cys-
toscopy potentially allows more complete detection and delin-
eation of tumours compared with WLC in bladder cancer
diagnosis. METHODS: Model inputs, including procedure costs
and clinical algorithms, are based on the bladder cancer diag-
nosis and treatment guidelines of the European Association of
Urology (EAU), literature review and Swedish clinical practice.
Several trials report less residual tumour at early re-resection fol-
lowing 5-ALA ﬂuorescence-assisted TURB with 59% to 80% rel-
ative reduction in recurrence in the ﬂuorescence group compared
to WLC. Based on these ﬁndings, the model assumed a conser-
vative 40% reduction in recurrence rate when Hexvix was used
alongside WLC to guide TURB. The model projects the ﬂow of
all newly diagnosed SBC patients, following histological risk
classiﬁcation at ﬁrst TURB, through treatment one year after
diagnosis. It covers Hexvix use in the operating room to guide
ﬁrst TURB in all patients with suspicion of bladder cancer and
all follow-up TURBs in patients with recurrent SBC. RESULTS:
In the Swedish population of newly diagnosed bladder cancer
patients, the model projects a reduction in the number of pro-
cedures required in the ﬁrst year compared to WLC alone, i.e.
29 cystectomies and 1961 TURBs with Hexvix compared to 52
and 2141 with WLC. Avoidance of these procedures would
result in $212,895 (SEK 1,561,908) reduction in costs to the
Swedish health service the ﬁrst year after diagnosis. CONCLU-
SIONS: The model predicts that use of Hexvix as an adjunct to
WLC for all initial and follow-up TURBs in the ﬁrst year fol-
lowing diagnosis will result in substantial cost savings for the
Swedish health service.
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OBJECTIVES: Primary (ﬁrst-cycle) prophylaxis with ﬁlgrastim
or second generation pegﬁlgrastim has been recommended in the
2006 ASCO and EORTC clinical guidelines when the risk of
febrile neutropenia (FN) is >20%. Recent studies reported sig-
niﬁcantly greater reduction of FN with pegﬁlgrastim than with
ﬁlgrastim, yet no study has compared their cost-effectiveness.
The study purpose was to evaluate the cost-effectiveness of
primary prophylaxis with pegﬁlgrastim versus 11-day use of ﬁl-
grastim (as recommended) in women with stage I-III breast
cancer receiving chemotherapy with moderate to high risk of FN
in Spain. METHODS: We constructed a decision-analytic model
from a health care payer’s perspective. Costs included costs for
drugs, drug administration, FN-related hospitalizations and sub-
sequent care, and were based on ex-factory price listing and 
literature. Effectiveness was measured as FN avoided and life-
years-gained (LYG). FN risk (varied by days of ﬁlgrastim), FN
case-fatality, relative dose intensity (RDI), and the impact of RDI
on survival were based on a comprehensive literature review and
expert panel validation. Breast cancer mortality and all-cause
mortality were from national cancer registries and vital statistics
report. Sensitivity analyses were conducted on key variables.
RESULTS: In addition to being more effective, pegﬁlgrastim
primary prophylaxis produced an average cost-savings of €32
per patient (€4243 pegﬁlgrastim versus €4275 ﬁlgrastim). Pegﬁl-
grastim reduced the absolute risk of FN by 5.5% (12.5% versus
7%) and had a LYG of 0.06 (16.48 versus 16.42 years). Age of
diagnosis and cancer stage had minimal impact on the results.
Key inﬂuencing factors included drug costs, relative risk of FN,
and drug administration cost. CONCLUSION: Primary pro-
phylaxis with pegﬁlgrastim in Spain appeared not only to be
more effective but also cost-saving compared with ﬁlgrastim used
for 11 days per cycle.
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In 2002, the medical services in Poland has been paid by the inde-
pendent public insurance institutions—Regional Cash of Ills. In
2003 the government established The National Fund of Health,
which integrate all regional insurance institutions and provide
identical availability of medical services for every patient in
Poland. OBJECTIVES: To assess the impact of changes in ﬁnanc-
ing of health services on costs structure from the payer perspec-
tives on the example of advanced ovarian cancer. METHODS:
Two regimens of chemotherapy were assessed: cisplatin-
cyclophospamide (CC) and cisplatin-paclitaxel (CP). The data of
medical resources consumed were collected retrospectively in
two oncology centers in Poland. All medical care consumption
(diagnostic tests, hospitalization, ambulatory care and medica-
tions) were estimated from the patients’ chart. Costs were
derived from the hospitals’ Financial Departments for the year
2002. And from the system used by National Fund of Health for
2006. All cost were in polish zloty. RESULTS: The total cost of
chemotherapy per patient in CP group in 2002 were 21,658 zl
and in 2006—14,594 zl, while the standard chemotherapy with
CC scheme were 9008 zl in 2002 and 6000 zl in 2006. In CP
group in 2002 the 72,5% of the total cost were the cost of cyto-
statics, while in 2006 they decreased to 52.2%. In CC group the
main costs (56%) in 2002 were additional medications such as
antiemetics and GCSF, while in 2006—51% of total costs was
the cost of hospitalization. CONCLUSIONS: The changes in
ﬁnancing of the health system decreased the total costs of ovarian
cancer chemotherapy. The main reason of it in PC group could
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be the registration of generic of paclitaxel in Poland. While the
changes in the cost structure in CC group could been produced
by including the costs of additional medication into the cost of
hospitalization.
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OBJECTIVE: The introduction of DRGs in 2004 requires
German hospitals to gain cost transparency and optimize budget
allocation. We compared two different chemo regimens (4× EC
followed by 4× docetaxel q21, EC→DOC vs. 6× CMF, day 1 +
8, q28) for patients with node positive primary breast cancer
regarding costs of resource consumption. METHODS: Data
were obtained piggyback during 2/2000–5/2002 on the German
prospective, longitudinal, randomized, multicenter Phase III
EC→DOC trial closed in 8/2005. Evaluation of diagnostic effort
was based on a comprehensive monocentric retrospective chart
review. To allocate costs to health care resources German tariffs
in €2005 and hospital databases were used. Costs were presented
from hospital provider perspective. Sensitivity and scenario
analyses were conducted. RESULTS: Altogether a cohort of 110
patients who received 1047 cycle days at 38 study centers was
analyzed. The average patient age was 52.4 years. Mean direct
costs for EC→DOC group totaled €8.459 per patient (N = 54).
Costs for cytostatics accounted for the largest portion with
€5.673 (67%), staff costs for drug application and pharmacy ser-
vices including transport averaged out €1.357 (16%), average
hospital basic costs were €414 (4.9%) and €376 (4.4%) for diag-
nostic effort and port or catheter implantation. Hospitals spent
€354 (4.2%) on supportive drugs, administration devices and
infusion bags and €313 (3.7%) on rehospitalisation (8 times in
7 patients). In contrast to rather expensive EC→DOC, CMF was
€3.486 less costly (−41.2%), but savings for CMF acquisition
cost with −€5.598 were partially compensated by higher costs
for medical and diagnostic effort or hospital hotel services.
Results were most sensitive to docetaxel acquisition cost and the
percentage of patients with incomplete chemotherapy. CON-
CLUSION: Our results will enable German hospitals to develop
strategies of ﬁnancing a consequential 70% budget increase
caused by introducing sequential docetaxel in adjuvant
chemotherapy of breast cancer.
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OBJECTIVES: Erlotinib, a new second-line therapy option in
patients with NSCLC, leads to similar overall survival improve-
ment but has a more favourable adverse events (AEs) proﬁle
compared to docetaxel and pemetrexed. The objective of the
present study was to compare the costs per patient treated with
erlotinib with those for docetaxel and pemetrexed for Germany
taking the management of AEs into account. METHODS: Direct
quarterly medical care costs per patient without considering AEs
(“base costs”) and those including costs of treating AEs (“total
costs”) were compared for the assessed therapy regimes. For cal-
culating base costs, costs for physician visits, drugs and drug
administration were considered. Total costs also included mean
costs for treating drug-related AEs grade 3/4 according to the US
National Cancer Institute classiﬁcation per patient under the
respective therapy. Resource utilisation data were obtained from
two multinational, randomized phase III trials. Further required
data was estimated based on national guidelines and prescribing
information for the drugs considered. The analysis was con-
ducted from the German payers’ perspective. Cost data were
derived from published sources for the year 2005. Due to the
short time horizon of one quarter the outcomes were not dis-
counted. One-way sensitivity analysis on cost data was per-
formed. RESULTS: Quarterly base costs per patient for erlotinib
are comparable to those for docetaxel (€8172 vs. €8055) and
about €7700 lower than those for pemetrexed (€8172 vs.
€15,870). Total quarterly costs per patient including costs of
treating AEs for erlotinib are about €1700 lower than for doc-
etaxel and about €8300 lower than for pemetrexed (€8374 vs.
€10,086 and €16,715, respectively). Sensitivity analyses con-
ﬁrmed the robustness of the results. CONCLUSIONS: Due to
the favourable tolerability proﬁle, the treatment with erlotinib is
cost-saving for the German health care system compared to doc-
etaxel and pemetrexed.
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Even if the clinical efﬁcacy of recombinant human erythropoi-
etin on chemotherapy-induced anemia was demonstrated, most
economic studies have given unfavorable results, whatever the
design and the outcome considered. OBJECTIVE: To calculate
the incremental cost-effectiveness ratio (ICER) of darbepoetin
alfa (Aranesp) as compared to standard palliative care in a
cohort of patients treated by chemotherapy for lung cancer in
clinical practice. METHOD: A Markov model was constructed
to evaluate the cost effectiveness ratio of one weekly injection
darbepoetin (Aranesp) compared with palliative standard care
(red blood transfusion if hg <8 g/dl) in the correction of
chemotherapy-induced anemia. Baseline probabilities and con-
sumed resources were calculated on the basis of a two-year ret-
rospective study, comparing two cohorts of patients treated by
chemotherapy who received (n = 94) or did not receive (n = 89)
Aranesp. The incremental cost-effectiveness ratio (ICER) was
calculated as the difference in direct costs from a health care per-
spective (transfusion requirement and anemia management
costs) divided by the difference in effect (changes in haemoglo-
bin levels). Sensitivity analysis was used to test uncertain data.
RESULTS: The use of Aranesp signiﬁcantly reduced the propor-
tion of patients needing transfusions (from 33.6% to 19.1%, 
p < 0.05) and the number of red cell units used by transfusion
(from 2.97 ± 1.47 to 2.11 ± 0.47, p < 0.01). Markov modeling
showed that the Aranesp strategy signiﬁcantly increased the
mean Hb level (13 ± 0.5 vs 11.9 ± 1 g/dl, p < 0.001), at the price
of an increase in the main cost (respectively 1732 ± 897 and 996
± 643€; p < 0.01). The incremental cost-effectiveness ratio was
estimated to be 202€ per haemoglobin gram gained. Sensitivity
analysis showed that the Aranesp strategy remained dominant in
most situations. CONCLUSION: Routine use of Aranesp
